Back to Results

Novartis AG ADR (NVS)

Novartis AG ADR is a depositary receipt representing common stock of Novartis AG, a Switzerland-based global pharmaceutical company listed on the NYSE under the ticker NVS. Through its underlying issuer, the business researches, develops, manufactures, markets, and sells medicines in Switzerland and international markets. Its portfolio includes treatments across cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. Key products named in the source include Entresto, Cosentyx, Kisqali, Promacta/Revolade, Tafinlar plus Mekinist, Jakavi, Tasigna, Xolair, Ilaris, Pluvicto, Sandostatin SC and Sandostatin LAR, Zolgensma, Lucentis, Leqvio, Lutathera, Scemblix, and Fabhalta. Novartis was incorporated in 1996 and is headquartered in Basel, Switzerland.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-NVS
$164.50
6.2% Upside
Fair
$154.56
-0.2% Downside
Fair
Great
—
—
3.0812
2.1%
July 21, 2026
20.9x
7.4x
5.0x
278.2 B
323.3 B
14.4%
97.6%
7.9
64.1%
129.6%
Valuation • Fair Value

Novartis AG ADR (NYSE-NVS) Fair Value by Valuation Model

Compare the primary fair value estimate for Novartis AG ADR (NYSE-NVS) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$164.50

Estimated upside of 6.2% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$182.17

Discounted cash flow valuation reference.

Ben Graham Formula Value

$82.03

Classic Ben Graham valuation formula reference.

DDM Fair Value

$225.34

Dividend discount model valuation reference.

EPV Fair Value

$109.77

Earnings power value estimate.

Comps Fair Value

$145.80

Comparable-company valuation reference.

Analyst Price Target

$154.56

Analysts imply downside of 0.2%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Novartis AG ADR (NYSE-NVS) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Novartis AG ADR (NYSE-NVS)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

56.578 B

Current operating scale indicator.

Revenue Forecast

56.661 B

Forward revenue estimate.

EBITDA

22.922 B

Current operating profitability reference.

EBITDA Forecast

22.917 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Novartis AG ADR (NYSE-NVS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Novartis AG ADR (NYSE-NVS)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-2.62

No elevated caution signal from this screen.

Altman Z-Score

7.9

Relatively strong balance-sheet zone.

FCF / Net Income

129.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Novartis AG ADR (NYSE-NVS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Novartis AG ADR (NYSE-NVS)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 21, 2026

Days to Earnings

0

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

2.1%

Income yield reference.

Upcoming Dividend

3.0812

Upcoming distribution amount.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

64.1%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Novartis AG ADR (NYSE-NVS), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Novartis AG ADR (NYSE-NVS) Stock Forecast & Technical Outlook

Review Novartis AG ADR (NYSE-NVS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Novartis AG ADR (NYSE-NVS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Novartis AG ADR (NYSE-NVS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Novartis AG ADR (NYSE-NVS) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Novartis AG ADR (NYSE-NVS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Novartis AG ADR (NYSE-NVS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Novartis AG ADR (NYSE-NVS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Novartis AG ADR (NYSE-NVS) has a Hold consensus, with 2 buy, 5 hold and 2 sell recommendations in the current data set.

Buy 2
Hold 5
Sell 2
FAQ • Fast Investor Answers

Novartis AG ADR (NYSE-NVS) Stock FAQ

Quick answers about Novartis AG ADR (NYSE-NVS) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$164.50
Estimated upside 6.2%
Valuation Rating
Undervalued
Estimated upside of 6.2%
Analyst Target
$154.56
Implied downside 0.2%
Financial Health
Great
Current financial-health read

The current fair value estimate for Novartis AG ADR (NYSE-NVS) is $164.50. This implies an estimated upside of 6.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 6.2% versus the current market price.

The available analyst price target for Novartis AG ADR (NYSE-NVS) is $154.56. The analyst target implies estimated downside of 0.2%.

The current financial health read for Novartis AG ADR (NYSE-NVS) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Novartis AG ADR (NYSE-NVS) is July 21, 2026.

Based on the current data, dividend yield is 2.1%, upcoming dividend amount is 3.0812.

The current P/E ratio listed for Novartis AG ADR (NYSE-NVS) is 20.9x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Novartis AG ADR is 278.2 B.

The current enterprise value listed for Novartis AG ADR is 323.3 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Novartis AG ADR is NYSE-NVS, and the stock is listed on NYSE.

Novartis AG ADR (NYSE-NVS) is listed on NYSE.

The current debt-to-total-capital ratio listed for Novartis AG ADR is 14.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Novartis AG ADR is 97.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on NYSE View more

Eli Lilly and Company (LLY) Eli Lilly and Company (LLY)
Johnson & Johnson (JNJ) Johnson & Johnson (JNJ)
Merck & Company Inc (MRK) Merck & Company Inc (MRK)
Novo Nordisk A/S (NVO) Novo Nordisk A/S (NVO)
Pfizer Inc (PFE) Pfizer Inc (PFE)
Bristol-Myers Squibb Company (BMY) Bristol-Myers Squibb Company (BMY)
GSK plc DRC (GSK) GSK plc DRC (GSK)
Takeda Pharmaceutical Co Ltd ADR (TAK) Takeda Pharmaceutical Co Ltd ADR (TAK)
HALEON PLC ADR (HLN) HALEON PLC ADR (HLN)
Teva Pharma Industries Ltd ADR (TEVA) Teva Pharma Industries Ltd ADR (TEVA)
Zoetis Inc (ZTS) Zoetis Inc (ZTS)
Elanco Animal Health (ELAN) Elanco Animal Health (ELAN)
Dr. Reddy’s Laboratories Ltd ADR (RDY) Dr. Reddy’s Laboratories Ltd ADR (RDY)
Veradermics Inc (MANE) Veradermics Inc (MANE)
Organon & Co (OGN) Organon & Co (OGN)
Prestige Consumer Healthcare Inc (PBH) Prestige Consumer Healthcare Inc (PBH)
Nuvation Bio Inc (NUVB) Nuvation Bio Inc (NUVB)
Bausch Health Companies Inc (BHC) Bausch Health Companies Inc (BHC)
Perrigo Company PLC (PRGO) Perrigo Company PLC (PRGO)
Alto Neuroscience Inc (ANRO) Alto Neuroscience Inc (ANRO)
Rafael Holdings Inc Class B (RFL) Rafael Holdings Inc Class B (RFL)
Impact Biomedical Inc (IBO) Impact Biomedical Inc (IBO)
China Pharma Holdings Inc (CPHI) China Pharma Holdings Inc (CPHI)
Nasus Pharma Ltd (NSRX) Nasus Pharma Ltd (NSRX)